Fifty leaders opposed to abortion sent a letter Thursday asking FDA nominee Heidi Overton to reverse Biden-era mailing of mifepristone ahead of her Senate HELP confirmation hearing and to restore earlier in-person rules during the ongoing review.

Tony Perkins of the Family Research Council said they had waited for the policy to end and the Trump FDA should act. The FDA paused in-person dispensing in 2021 and made it permanent in 2023 after Dobbs, allowing mailing from permissive states into restrictive ones, with sender shields in some states and reports of men obtaining pills online to pressure women. An April 2025 report cited in the letter found 11 percent of women had sepsis, infection or hemorrhage within 45 days, versus under 0.5 percent on the FDA label. About 20 states passed new limits after Dobbs but national abortion numbers rose, with pills also coming from overseas.